Erratum to: Canagliflozin: First Global Approval

Durvalumab: First Global Approval

Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progress...

Erratum to: Armentum: a hybrid direct search optimization methodology

In the original publication of this article unfortunately the co-authors were omitted. The two co-authors are displayed now.

Erratum

Erratum to: Global Health Workforce Labor Market Projections for 2030

BACKGROUND In low- and middle-income countries, scaling essential health interventions to achieve health development targets is constrained by the lack of skilled health professionals to deliver services. METHODS We take a labor market approach to project future health workforce demand based on an economic model based on projected economic growth, demographics, and health coverage, and using ...

Approval of the first biosimilar antibodies in Europe

In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion's Remsima® and Hospira's Inflectra®), and recommended that they be approved for marketing in the European Union (EU). The European Commission's decision ...